Godavari Drugs Complete Financial Statements
In FYNone, Godavari Drugs (GODAVARI) reported revenue ₹111 Cr, net profit ₹4 Cr and EPS ₹5.20, with a net profit margin of 3.7% and ROE of 5.3%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GODAVARI Revenue, Net Profit & EBITDA — Year-on-Year Growth
GODAVARI YoY (March 2026 vs Period) — revenue +3.7%, expenses +4.2%. Compare with GODAVARI fair price to assess whether the stock is under or overvalued.
GODAVARI Income Statement — Revenue, EBITDA & Net Profit
Godavari Drugs revenue ₹111 Cr, EBITDA ₹11 Cr, net profit ₹4 Cr, EPS ₹5.20 (None) — net profit margin 3.7%. For live price, earnings ratios and company overview, see Godavari Drugs share price screener.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111 | 107 | 114 | 157 | 160 | 161 | 123 | 96 | 84 | 65 | 76 | 71 | 55 |
| Expenses | 100 | 96 | 102 | 143 | 150 | 150 | 113 | 90 | 78 | 60 | 70 | 67 | 49 |
| EBITDA | 11 | 11 | 13 | 14 | 11 | 12 | 10 | 6 | 6 | 5 | 6 | 5 | 6 |
| Operating Profit Margin % | 9.00% | 10.00% | 10.00% | 8.00% | 6.00% | 7.00% | 8.00% | 6.00% | 7.00% | 6.00% | 7.00% | 6.00% | 11.00% |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 4 | 4 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 1 |
| Profit Before Tax | 5 | 5 | 6 | 7 | 5 | 7 | 6 | 2 | 2 | 1 | 3 | 2 | 5 |
| Tax | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 1 |
| Net Profit | 4 | 4 | 4 | 6 | 4 | 5 | 4 | 2 | 1 | 1 | 2 | 1 | 4 |
| Earnings Per Share (₹) | 5.20 | 5.43 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 | 1.60 | 1.10 | 2.40 | 1.79 | 4.84 |
GODAVARI Balance Sheet — Assets, Liabilities & Shareholders' Equity
GODAVARI total assets ₹200 Cr, total equity ₹76 Cr, total liabilities ₹ Cr (2026) — ROE 5.3%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 200 | 143 | 135 | 121 | 101 | 91 | 84 | 74 | 63 | 56 | 51 | 35 |
| Current Assets | 112 | 79 | 89 | 87 | 74 | 68 | 61 | 57 | 47 | 43 | 40 | 27 |
| Fixed Assets | 30 | 33 | 27 | 25 | 26 | 22 | 14 | 15 | 15 | 13 | 9 | 7 |
| Capital Work in Progress | 57 | 30 | 18 | 9 | 1 | 1 | 9 | 2 | 1 | 0 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 114 | 81 | 90 | 87 | 75 | 68 | 61 | 57 | 48 | 43 | 41 | 27 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 40 | 27 | 14 | 14 | 14 | 16 | 12 | 9 | 9 | 6 | 5 | 5 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 76 | 43 | 39 | 33 | 30 | 24 | 20 | 18 | 17 | 16 | 14 | 13 |
| Share Capital | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves & Surplus | 60 | 36 | 31 | 26 | 22 | 17 | 13 | 11 | 10 | 9 | 7 | 6 |
GODAVARI Cash Flow Statement — Operating, Investing & Financing
Godavari Drugs operating cash flow ₹1 Cr, investing ₹-26 Cr, financing ₹37 Cr, net cash flow ₹12 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 11 | 18 | 13 | 11 | 1 | 6 | 4 | 4 | 5 | -5 | -6 |
| Investing Activities | -26 | -20 | -13 | -9 | -5 | -1 | -7 | -2 | -3 | -3 | -2 | 0 |
| Financing Activities | 37 | 8 | -6 | -4 | -6 | 0 | 0 | -2 | 0 | -2 | 7 | 6 |
| Net Cash Flow | 12 | 0 | -1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |